undamentalytics Newsletter
Sign in

Pulse Biosciences, Inc. cash flow statement

In fiscal 2025, Pulse Biosciences, Inc.'s operations generated −$54.1m of cash; it spent $315,000 on capital projects, leaving free cash flow of −$54.4m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−35−54−47−33−36−54−61
Depreciation and amortisation0011100
Stock-based pay101557142117
Capital spending0000000
Free cash flow−36−55−47−33−36−54−61
Free cash flow after stock pay−46−69−53−40−50−76−79
Shares issued2957150———

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: IMDX vs PLSEICU vs PLSECODX vs PLSE

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Pulse Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pulse Biosciences, Inc.